A Phase 2 interventional study of Carboplatin and Paclitaxel in Breast Carcinoma, sponsored by University of California, Irvine. Active, not recruiting at 1 site in United States. Open to female participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-12.
Sponsored by University of California, Irvine · Phase 2, Interventional, and Treatment
How we know · 14 judgments · 4 readings being read again
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 131 studies testing bevacizumab in Breast Neoplasms — 9 open to participants now, 10 under way, none of them phase 3. Bevacizumab · Breast Neoplasms.
Among the 131 studies testing bevacizumab in Breast Neoplasms, this one is the 36th largest by enrollment of the 130 interventional ones that give a count, is the only one that started in 2015, is one of 89 in phase 2, and was the 116th registered.
14,855 studies on the registry are indexed under Breast Neoplasms; 3,321 are open to participants now.
Browse Breast Neoplasms studies →9 of the 131 studies testing bevacizumab in Breast Neoplasms are open now, in 12 countries. Recruiting first, the newest first:
Fudan University · Sites in China
Ages 18–70 · Women only
Yukinori Ozaki · Sites in Japan
Ages 18+
Tongji Hospital · Sites in China
Ages 18+
Lebanese University · Sites in Lebanon
Ages 18+
Henan Cancer Hospital · Sites in China
Ages 18–70 · Women only
By country, each count listing its studies:
Bevacizumab: first FDA approval 2004 (AVASTIN), first EMA approval 2005. What it is approved for, and how studies give it, is on its page →
Of the 2,403 Breast Neoplasms studies recruiting now, 1,574 (66%) set no upper age limit and 591 (25%) stop at 75 or younger; 103 take children under 18; 215 take healthy volunteers.
This study: 18 Years and older · female · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
131 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 15 · Phase 2 96 · Phase 3 19 · Phase 4 4
First in 2000; this study’s year is marked. 1 started in 2015.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 120 is above the median of 72 across 10,921 interventional studies indexed under Breast Neoplasms.
Median enrollment 58 across the 130 interventional studies. Of the 106 that completed or were terminated, 59 (56%) have results posted.
This tab as a report to print or save as PDF → With an account.
27 of 131 have an industry lead sponsor. The 10 most frequent:
University of California, Irvine is the lead sponsor of 478 studies on the registry; 99 are open to participants now.
Of its 41 completed or terminated interventional studies of FDA-regulated products, 30 (73%) have results posted.
18 studies in Breast Neoplasms by University of California, Irvine: 3 open now, 4 under way, none of them phase 3. Of 9 finished, 4 (44%) have results posted.
Among the 18 studies in Breast Neoplasms by University of California, Irvine, this one is the 2nd largest by enrollment of the 11 interventional ones that give a count, is one of 3 that started in 2015, is one of 7 in phase 2, and was the 12th registered.
University of California, Irvine’s Breast Neoplasms studies by the year they started, since 1995.
3 of the studies testing bevacizumab in Breast Neoplasms that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05398861Henan Cancer HospitalUtidelone Combined With Bevacizumab in the Treatment of ≥ 2 Lines of HER-2 Negative Advanced Breast Cancer | 2026-12-30 |
| NCT07359404YING FANSacituzumab Govitecan Plus Bevacizumab in Metastatic TNBC | 2026-12-31 |
| NCT07150208Fudan UniversityT-DXd With or Without Bevacizumab for HER2-low Breast Cancer With Brain Metastasis | 2027-09 |
Add all 3 to your calendar (.ics) → With an account.
Among the 131 studies testing bevacizumab in Breast Neoplasms, from their registry updates:
Among University of California, Irvine’s 18 in Breast Neoplasms:
This tab as a report to print or save as PDF → With an account.
The purpose of this phase II is to study the efficacy and toxicity of carboplatin and paclitaxel with pertuzumab and trastuzumab in HER2 positive and carboplatin and paclitaxel with bevacizumab in HER2 negative in the neoadjuvant setting for the treatment of breast cancer.
OBJECTIVES The study component is to evaluate the treatment response and toxicity of the protocol.
Objectives for treatment study component:
1.1 To estimate 2-year progression-free survival in patients with breast cancer with tumor more than 1 cm and/or with clinically detected lymph node treated with neoadjuvant weekly Carboplatin and Paclitaxel combined with Trastuzumab + Pertuzumab in HER2-positive disease or with Bevacizumab in HER2-negative disease.
1.2 To measure the microscopic complete pathological response (pCR) rates defined as ypT0 or ypTis tumors in patients treated with this regimen in the neoadjuvant setting.
1.3 To assess complete clinical response (cCR) rates after treatment by physical exam and imaging tests (ultrasonography, mammography, or magnetic resonance imaging) clinical objective response rate (by Response Evaluation Criteria In Solid Tumors (RECIST)) 1.4 To determine the toxicity of this regimen. 1.5 To determine treatment adherence and delivered dose intensity of this regimen.
1.6 To assess the correlation between pCR and cCR. 1.7 To determine the rate of breast conservation following neoadjuvant therapy. 1.8 Determine treatment efficacy according to subgroups defined according to stage and receptor status.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Normal cardiac function must be documented within 90 days prior to registration either via an ECHO or or per physician's review of symptoms and medical history. If an ECHO is performed as standard of care, the ejection fraction must be above the normal limit of the institution.. If not available in the medical chart, the ECHOs or MUGAs are not required to be repeated for research purposes.
a. Date of Echo or multigated acquisition (MUGA) (within 90 days) if performed
Staging work-up prior to registration
Laboratory requirements:
Hematology:
Hepatic Function
Renal Function
- Creatinine \<1.5x ULN
Proteinuria
- Random urine total protein \<100mg/dL. Urine Protein Creatinine (UPC) ratio \<2g
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
HER2 is a protein, made from the ERBB2 gene, that drives the growth of some cancers. A study may look for a level of the protein, extra copies of the gene, or a particular change in it.
In breast cancer, protein tests are read as HER2-positive, HER2-low or HER2-negative; other cancers use their own rules. Check which test result the study requires.
The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.
The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.
It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Histologically or cytologically confirmed
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Measurable disease
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HER2
HER2 is a protein, made from the ERBB2 gene, that drives the growth of some cancers. A study may look for a level of the protein, extra copies of the gene, or a particular change in it.
In breast cancer, protein tests are read as HER2-positive, HER2-low or HER2-negative; other cancers use their own rules. Check which test result the study requires.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
LVEF (left ventricular ejection fraction)
The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Absolute neutrophil count (ANC)
The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.
It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Platelets
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Bilirubin
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Biopsy and archival tissue
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Carboplatin weekly 12 doses Paclitaxel weekly 12 doses Bevacizumab every other week, 5 doses
Drug: Carboplatin · Drug: Paclitaxel · Drug: Bevacizumab
Carboplatin weekly 12 doses Paclitaxel weekly 12 doses Trastuzumab weekly 12 doses Pertuzumab every 3 weeks, 4 doses
Drug: Carboplatin · Drug: Paclitaxel · Drug: Trastuzumab · Drug: Pertuzumab
Area Under the Curve (AUC) 2 IV over 60 minutes weekly for 12 doses
Also known as: Paraplatin
80 mg/m\^2 IV over 1-3 hours weekly for 12 doses
Also known as: Taxol
10mg/kg IV over 90 or 60 or 30 minutes every other week for 5 doses
Also known as: Avastin
4mg/kg induction, followed by weekly 2mg/kg IV-induction over 90 minutes, then weekly over 30-60 minutes for 12 doses
Also known as: Herceptin
840mg induction, followed by 420mg every 3 weeks IV-induction over 60 minutes, then every 3 weeks over 30-60 minutes for 4 doses
Also known as: Perjeta
2-year Progression Free Survival in Patients Treated With Weekly Carboplatin and Paclitaxel Combined With Either Trastuzumab and Pertuzumab for HER2-positive Patients or Bevacizumab for HER2-negative Patients in the Neoadjuvant Setting
Progression of disease-A new lesion or a greater than or equal to 25% increase in the product of the largest perpendicular diameters of any one lesion on clinical exam or by U/S or MRI Survival-from date of registration to date of death
Time frame: 2 years
Clinical Complete Response Rates
Clinical complete response (cCR)-Normal breast on physical exam. No mass, no thickening, no erythema, no peau d'orange
Time frame: 2 years
Pathologic Complete Response Rates
Pathologic complete response (pCR)-No histologic evidence of microscopic invasive tumor at the primary tumor site in the surgical specimen (ypT0 or DCis)
Time frame: 2 years
Number of Toxicities in Carboplatin+Paclitaxel+Bevacizumab (HER2) Arm
This study will utilize the Common Terminology Criteria for Adverse Events (CTCAE) Version 4.0 for toxicity and Adverse Event reporting.
Time frame: Up to 42 days after discontinued treatment
Number of Toxicities in Carboplatin+Paclitaxel+Trastuzumab+Pertuzumab (HER2+)
This study will utilize the Common Terminology Criteria for Adverse Events (CTCAE) Version 4.0 for toxicity and Adverse Event reporting.
Time frame: Up to 42 days after discontinued treatment
| Milestone | Carboplatin + Paclitaxel+ Bevacizumab (HER2-) | Carboplatin + Paclitaxel + Trastuzumab+ Pertuzumab (HER2+) |
|---|---|---|
| Started | 72 | 48 |
| Completed | 72 | 48 |
| Not completed | 0 | 0 |
Progression of disease-A new lesion or a greater than or equal to 25% increase in the product of the largest perpendicular diameters of any one lesion on clinical exam or by U/S or MRI Survival-from date of registration to date of death
| Percentage | Arm 1: Her2-negative (HER2-) | Arm 2: Her2-positive (HER2+) |
|---|---|---|
| 2-year Progression Free Survival in Patients Treated With Weekly Carboplatin and Paclitaxel Combined With Either Trastuzumab and Pertuzumab for HER2-positive Patients or Bevacizumab for HER2-negative Patients in the Neoadjuvant Setting | 68.2 (51.7 to 84.7) | 90.3 (81.1 to 99.5) |
Clinical complete response (cCR)-Normal breast on physical exam. No mass, no thickening, no erythema, no peau d'orange
Results for this outcome have not been posted.
Pathologic complete response (pCR)-No histologic evidence of microscopic invasive tumor at the primary tumor site in the surgical specimen (ypT0 or DCis)
Results for this outcome have not been posted.
This study will utilize the Common Terminology Criteria for Adverse Events (CTCAE) Version 4.0 for toxicity and Adverse Event reporting.
Results for this outcome have not been posted.
This study will utilize the Common Terminology Criteria for Adverse Events (CTCAE) Version 4.0 for toxicity and Adverse Event reporting.
Results for this outcome have not been posted.
Collected over Adverse events and serious adverse events will begin to be collected when the participant starts treatment until 30 days after the end of treatment. Approximately 6 months.. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Arm 1 | 11/72 (15.3%) | 11/72 (15.3%) | 68/72 (94.4%) |
| Arm 2 | 4/48 (8.3%) | 4/48 (8.3%) | 40/48 (83.3%) |
| Event | Arm 1 | Arm 2 |
|---|---|---|
| DiarrheaGastrointestinal disorders | 2/72 | 1/48 |
| Skin infectionInfections and infestations | 2/72 | 0/48 |
| Febrile neutropeniaBlood and lymphatic system disorders | 1/72 | 1/48 |
| ConstipationGastrointestinal disorders | 0/72 | 1/48 |
| AppendicitisInfections and infestations | 0/72 | 1/48 |
| Gastric perforationGastrointestinal disorders | 1/72 | 0/48 |
| DiverticulitisGastrointestinal disorders | 1/72 | 0/48 |
| Oral hemorrhageGastrointestinal disorders | 1/72 | 0/48 |
| Rectal BleedingGastrointestinal disorders | 1/72 | 0/48 |
| Nose BleedGeneral disorders | 1/72 | 0/48 |
| Event | Arm 1 | Arm 2 |
|---|---|---|
| DiarrheaGastrointestinal disorders | 25/72 | 34/48 |
| FatigueGeneral disorders | 41/72 | 19/48 |
| NauseaGastrointestinal disorders | 37/72 | 24/48 |
| EpixstasisReproductive system and breast disorders | 37/72 | 9/48 |
| ConstipationGastrointestinal disorders | 35/72 | 5/48 |
| Neutrophil Count IncreasedInvestigations | 34/72 | 20/48 |
| AlopeciaSkin and subcutaneous tissue disorders | 33/72 | 10/48 |
| Peripheral Sensory NeuropathyNervous system disorders | 31/72 | 18/48 |
| InsomniaPsychiatric disorders | 25/72 | 5/48 |
| HeadacheNervous system disorders | 23/72 | 11/48 |
| Age, Continuous(Years) | Carboplatin + Paclitaxel+ Bevacizumab (HER2-) | Carboplatin + Paclitaxel + Trastuzumab + Pertuzumab (HER2+) | Total |
|---|---|---|---|
| Median | 52 (28 to 76) | 53.5 (26 to 81) | 53 (26 to 81) |
| Sex: Female, Male(Participants) | Carboplatin + Paclitaxel+ Bevacizumab (HER2-) | Carboplatin + Paclitaxel + Trastuzumab + Pertuzumab (HER2+) | Total |
|---|---|---|---|
| Female | 72 | 48 | 120 |
| Male | 0 | 0 | 0 |
| Ethnicity (NIH/OMB)(Participants) | Carboplatin + Paclitaxel+ Bevacizumab (HER2-) | Carboplatin + Paclitaxel + Trastuzumab + Pertuzumab (HER2+) | Total |
|---|---|---|---|
| Hispanic or Latino | 33 | 17 | 50 |
| Not Hispanic or Latino | 38 | 30 | 68 |
| Unknown or Not Reported | 1 | 1 | 2 |
| Race (NIH/OMB)(Participants) | Carboplatin + Paclitaxel+ Bevacizumab (HER2-) | Carboplatin + Paclitaxel + Trastuzumab + Pertuzumab (HER2+) | Total |
|---|---|---|---|
| American Indian or Alaska Native | 1 | 0 | 1 |
| Asian | 17 | 11 | 28 |
| Native Hawaiian or Other Pacific Islander | 1 | 1 | 2 |
| Black or African American | 1 | 1 | 2 |
| White | 37 | 30 | 67 |
| More than one race | 3 | 0 | 3 |
| Unknown or Not Reported | 12 | 5 | 17 |
| Region of Enrollment(participants) | Carboplatin + Paclitaxel+ Bevacizumab (HER2-) | Carboplatin + Paclitaxel + Trastuzumab + Pertuzumab (HER2+) | Total |
|---|---|---|---|
| United States | 72 | 48 | 120 |
PDFs hosted by the registry, ClinicalTrials.gov.
The record gives a start of Apr 2015, a primary completion of Nov 2023 and a completion of Dec 2036. It does not say whether these dates are actual or estimated.
Results were first posted in Nov 2026, 3 years after primary completion.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is active, not recruiting, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Bevacizumab · Trastuzumab · Pertuzumab
University of California, Irvine →